BMC reiterated its Buy rating on Allos Therapeutics (NASDAQ:
ALTH). At the same time, BMC left its rating unchanged at $6 after the company's new drug, Istodax, was given a PTCL approval.
On Thursday, Allos added 8.65% to its value to close the day at $2.01.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.